Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 7/20 | 0.42 |
| ▸ | RHOA | P61586 | 7/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.41 |
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660828 | 0.90 | RHOC (0.47) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL977000 | 0.89 | RHOC (0.41) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3429829 | 0.88 | UTS2R (0.40) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3430317 | 0.88 | DDR1 (0.38) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3408843 | 0.88 | UTS2R (0.39) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3406266 | 0.88 | UTS2R (0.39) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3408137 | 0.86 | DDR1 (0.36) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL3408675 | 0.86 | DRD2 (0.40) | F2 | |
| SCHEMBL976068 | 0.86 | UTS2R (0.38) | RHOCRHOADDR1NNMTF2 | |
| SCHEMBL977822 | 0.86 | MEN1 (0.37) | RHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | claimed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | RHOC 442/4885RHOA 75/4885DDR1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.